Verastem, Inc. (NASDAQ:VSTM)’s share price traded up 1.1% during mid-day trading on Thursday . The stock traded as high as $5.55 and last traded at $4.98. 2,933,055 shares were traded during trading, an increase of 127% from the average session volume of 1,293,490 shares. The stock had previously closed at $4.92.

Several equities analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target (up previously from $6.50) on shares of Verastem in a research note on Thursday. Zacks Investment Research raised Verastem from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research note on Thursday, July 13th. ValuEngine lowered Verastem from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $6.00 price target on shares of Verastem in a research note on Wednesday. Finally, Cantor Fitzgerald raised Verastem from a “neutral” rating to an “overweight” rating and set a $2.00 price target on the stock in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $5.04.

The company’s market cap is $195.69 million. The firm’s 50-day moving average is $3.63 and its 200-day moving average is $2.48.

Verastem (NASDAQ:VSTM) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. On average, equities research analysts expect that Verastem, Inc. will post ($1.38) EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp grew its position in shares of Verastem by 40.3% in the 2nd quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 21,178 shares during the last quarter. Howland Capital Management LLC grew its position in shares of Verastem by 16.5% in the 2nd quarter. Howland Capital Management LLC now owns 294,007 shares of the biopharmaceutical company’s stock valued at $641,000 after buying an additional 41,616 shares during the last quarter. Alpine Woods Capital Investors LLC bought a new stake in shares of Verastem in the 2nd quarter valued at about $109,000. TFS Capital LLC bought a new stake in shares of Verastem in the 1st quarter valued at about $113,000. Finally, Vanguard Group Inc. grew its position in shares of Verastem by 10.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,143,642 shares of the biopharmaceutical company’s stock valued at $2,493,000 after buying an additional 107,029 shares during the last quarter. Hedge funds and other institutional investors own 24.19% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Verastem, Inc. (VSTM) Trading 1.1% Higher” was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/09/verastem-inc-vstm-trading-1-1-higher-2.html.

Verastem Company Profile

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.